Equities

Silence Therapeutics PLC

Silence Therapeutics PLC

Actions
  • Price (EUR)15.00
  • Today's Change-0.50 / -3.23%
  • Shares traded4.00
  • 1 Year change+78.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 14:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments547174
Total Receivables, Net19178.49
Total Inventory------
Prepaid expenses8.168.204.31
Other current assets, total----0
Total current assets819786
Property, plant & equipment, net1.812.201.94
Goodwill, net7.848.017.59
Intangibles, net0.280.320.02
Long term investments0.280.280.30
Note receivable - long term------
Other long term assets2.58----
Total assets9410896
LIABILITIES
Accounts payable2.633.194.07
Accrued expenses9.438.866.53
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.180.180.14
Other current liabilities, total5.539.454.43
Total current liabilities182215
Total long term debt0.090.260
Total debt0.270.450.14
Deferred income tax------
Minority interest------
Other liabilities, total596373
Total liabilities778588
SHAREHOLDERS EQUITY
Common stock5.945.394.49
Additional paid-in capital251227184
Retained earnings (accumulated deficit)(242)(212)(182)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.952.091.54
Total equity17228.53
Total liabilities & shareholders' equity9410896
Total common shares outstanding11910890
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.